Opinion|Videos|June 26, 2024

Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, from Mayo Clinic opens a conversation around CDK4/6 inhibitor prescription for patients diagnosed with early breast cancer.

Video content above is prompted by the following:

  • In the adjuvant treatment of HR-positive/HER2-negative early breast cancer, endocrine therapy has traditionally played a crucial role, with CDK4/6 inhibitors becoming more prominent in recent years.
  • What factors related to the patient or disease influences your decision to prescribe a CDK4/6 inhibitor in this setting?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo